US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,718.28

-0.7418-0.04%

Number of Gainers:1

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,730.47

Open:1,728.65

Low:1,714.45

Close:1,719.02

Volume:3.92M

Turnover:556.99M

Market Cap:442.84B

Float Cap:434.61B

Loading ...

H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi

Novartis MS Trials Open Door to Multibillion-Dollar Sales Opportunity

Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials

Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement

Novartis's Multiple Sclerosis Trial Results Match Best Hopes

US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy

Novartis up Nearly 6%, on Pace for Largest Percent Increase Since March 2023

【US Pre-Market】US Futures and Chip Stocks Fall as Global Bond Sell-Off Deepens; Gold Drops Below $4,400, Brent Crude Tops $92

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Why Novartis Stock is Heading for Its Best Day Since 2023 After 3 Patient Deaths

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials

MT Newswires Live

Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise

Novartis Pauses Autoimmune Cell Therapy Studies After Deaths

Novartis AG Falls Monday, Outperforms Market

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/BK4578/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1718.2825,"timestamp":1789067785155,"preClose":1719.0243,"halted":0,"volume":3924336,"delay":0,"changeRate":-0.000432,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-0.741821,"latestTime":"09-10 15:16:25 EDT","open":1728.6481,"high":1730.4697,"low":1714.4503,"amount":556989350.827679,"amplitude":0.009319,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.314749,"peRate":46.628821,"turnoverRate":0.00127,"increases":1,"decrements":1,"flats":0,"marketCap":442835189760,"floatMarketCap":434610077696},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1730.4697,"amplitude":0.009319,"preClose":1719.0243,"low":1714.4503,"pbRate":"8.314749","latestPrice":1718.2825,"volume":3924355,"delay":0,"open":1728.6481,"prevYearClose":1612.5378,"prevWeekClose":1911.2454,"prevMonthClose":1830.2803,"prevQuarterClose":1768.1697,"fiveDayClose":1922.4193,"twentyDayClose":1781.5829,"sixtyDayClose":1720.4836,"secType":"PLATE","market":"US","turnoverRate":0.00127,"peRate":46.628821,"marketCap":442863812608,"floatMarketCap":434637832192,"timestamp":1789067786445,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":1,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664850457","title":"H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2664850457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664850457?lang=en_us&edition=fundamental","pubTime":"2026-09-01 23:35","pubTimestamp":1788276922,"startTime":"0","endTime":"0","summary":"After Novartis (NVS) announced topline data from the REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis, H.C. Wainwright analyst E...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-novartis-success-in-rms-trials-does-not-impact-tgs-briumvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-novartis-success-in-rms-trials-does-not-impact-tgs-briumvi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","LU0070302665.USD","IE00B4R5TH58.HKD","BK4578","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4007","LU0320765489.SGD","IE0009355771.USD","LU0208291251.USD","BK4585","MEDX","PPH","NVS","BK4532","BK4588","LU0211331839.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664527668","title":"Novartis MS Trials Open Door to Multibillion-Dollar Sales Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2664527668","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664527668?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:27","pubTimestamp":1788272820,"startTime":"0","endTime":"0","summary":"1427 GMT - Novartis's latest trial results for a multiple sclerosis drug suggest a multibillion-dollar sales opportunity is within the Swiss drugmaker's reach, analysts at J.P. Morgan say in a research note. The results for Novartis's Rhapsido reduce risk on a sales opportunity of at least $2 billion to $3 billion in relapsing multiple sclerosis alone, according to JPM. Given that consensus forecasts for 2030 sales from the drug currently stand at $3.4 billion, mainly from skin conditions, consensus estimates could see significant upgrades after the results, the analysts say. That said, detailed data are required to assess the drug's potential relative to Roche's fenebrutinib and so-called anti-CD20 therapies, a different class of medicines, they add. Novartis shares jump 6.3%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","MEDX","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","LU0208291251.USD","IE00B2B36J28.USD","BK4578","IE0009355771.USD","BK4532","IE00B4R5TH58.HKD","PPH","LU0320765489.SGD","BK4588","LU0070302665.USD","LU0211331839.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664852288","title":"Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2664852288","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664852288?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:17","pubTimestamp":1788272261,"startTime":"0","endTime":"0","summary":"Novartis ($NVS) stock rose about 6% at the time of writing on Tuesday, after the Swiss drugmaker reported positive results from two late-stage tria...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novartis-stock-nvs-pops-as-multiple-sclerosis-drug-shows-positive-results-in-late-stage-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novartis-stock-nvs-pops-as-multiple-sclerosis-drug-shows-positive-results-in-late-stage-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4007","LU0070302665.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4578","BK4532","NVS","LU0211331839.USD","BK4588","IE0009355771.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","BK4585","PPH","IE00BJT1NW94.SGD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664785240","title":"Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2664785240","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664785240?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:15","pubTimestamp":1788272126,"startTime":"0","endTime":"0","summary":"• Remibrutinib succeeded in Phase III multiple sclerosis trials, showing clinical superiority.\n• Novartis paused eight early-stage CAR-T trials following three patient deaths.\n• The company reports $56.33B annual revenue and $13.98B net profit.","market":"hk","thumbnail":"https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20251024/Novartis-369e71de347f479fa3f300f9d7904bc5.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262144163-market-movers-nvs-20260901","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0320765489.SGD","IE0002141913.USD","BK4578","IE0009355771.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","BK4588","NVS","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4532","LU0070302665.USD","BK4007","BK4585","MEDX","PPH","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664150852","title":"Novartis's Multiple Sclerosis Trial Results Match Best Hopes","url":"https://stock-news.laohu8.com/highlight/detail?id=2664150852","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664150852?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:14","pubTimestamp":1788272040,"startTime":"0","endTime":"0","summary":"1414 GMT - Novartis's trial results for a multiple sclerosis drug are in line with a blue-sky scenario, UBS analysts say in a research note. The Swiss drugmaker's results from two late-stage studies point to a greater reduction in annualized relapse rates with its Rhapsido compared to Sanofi's Aubagio, with no liver safety issues, the analysts say. These results suggest Novartis's drug might be at least a best-in-class oral medicine for the disease, according to UBS. UBS estimates that there's a 50% probability the drug's sales for relapsing multiple sclerosis reach $4.5 billion. Novartis shares jump 6.2%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205193047.USD","LU1863844665.USD","LU0240878834.USD","IE00BFTCPJ56.SGD","MTCH","IE0002141913.USD","LU0320765489.SGD","BK4118","IE0034235071.USD","BK4578","LU0205194284.USD","LU1829250122.USD","IE0009355771.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","BK4508","LU0211331839.USD","LU3187612489.SGD","BK4588","SOCL","IE00BJT1NW94.SGD","NVS","IE00B4R5TH58.HKD","LU0240877869.USD","BK4077","BK4532","BK4534","UBS","BK4549","LU0070302665.USD","LU1863844749.USD","BK4007","BK4585","MEDX","PPH","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148610163","title":"US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1148610163","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148610163?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:00","pubTimestamp":1788271219,"startTime":"0","endTime":"0","summary":"On Tuesday, shares of Novartis AG (NVS.US) climbed more than 5% to trade at $160.82 apiece. The surge follows the company's announcement that its investigational oral therapy, remibrutinib, met key...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","BK4578","IE00BJJMRZ35.SGD","01477","PPH","IE0002141913.USD","LU0070302665.USD","IE00B2B36J28.USD","BK4532","BK1574","MEDX","NVS","LU0211331839.USD","LU0320765489.SGD","BK4588","LU0208291251.USD","BK1191","IE0009355771.USD","IE00BJT1NW94.SGD","BK4585","IE00BFTCPJ56.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664485406","title":"Novartis up Nearly 6%, on Pace for Largest Percent Increase Since March 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2664485406","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664485406?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:54","pubTimestamp":1788270840,"startTime":"0","endTime":"0","summary":"Novartis AG Sponsored ADR  is currently at $160.98, up $8.92 or 5.87%--Would be highest close since March 10, 2026, when it closed at $161.59--On pace for largest percent increase since March 27, 2023, when it rose 8%--Snaps a four day losing streak--Up 16.76% year-to-date--Down 4.53% from its all-time closing high of $168.62 on Feb. 27, 2026--Up 27.12% from 52 weeks ago , when it closed at $126.64--Down 4.53% from its 52-week closing high of $168.62 on Feb. 27, 2026--Up 32.17% from its 52-week closing low of $121.80 on Oct. 29, 2025--Traded as high as $163.57; highest intraday level since March 4, 2026, when it hit $165.69--Up 7.57% at today's intraday high; largest intraday percent increase since March 27, 2023, when it rose as much as 8.37%All data as of 9:52:05 AM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","BK4588","NVS","BK4007","PPH","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","MEDX","IE00B2B36J28.USD","LU0208291251.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IE0002141913.USD","BK4585","BK4532","BK4578","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859859","title":"【US Pre-Market】US Futures and Chip Stocks Fall as Global Bond Sell-Off Deepens; Gold Drops Below $4,400, Brent Crude Tops $92","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859859","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859859?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:01","pubTimestamp":1788264098,"startTime":"0","endTime":"0","summary":"TradingKey - On Tuesday (September 1) Eastern Time, futures on the three major U.S. stock indexes fell across the board in pre-market trading. Geopolitical risks escalated sharply after two supertankers were hit by unidentified projectiles in the Strait of Hormuz, driving international oil prices further up. Meanwhile, the global bond market sell-off persisted, pushing long-term government bond yields in major economies to multi-year highs and significantly dampening market risk appetite.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20240105/eb0f4a7f5f55ac405df7e752c6038bc8.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20240105/eb0f4a7f5f55ac405df7e752c6038bc8.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262143844-us-pre-market-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GOU","IE00BDGV0183.EUR","IE00BYXW3230.USD","LU0274383776.USD","LU2247934214.USD","LU0266013472.USD","LU2461242641.AUD","WDC","NVDA","LU2065171311.SGD","LU0312595415.SGD","LU1934455194.USD","BK4605","FCUS","IE0002270589.USD","BK4612","IE00B19Z8X17.USD","LU0323240290.USD","FDRV","LU0256863902.USD","LU1323610961.USD","BK4532","LU1670756490.USD","LU2023251221.USD","SNDQ","LU2098885051.SGD","LU2505996681.GBP","MRVU","GAMR","NVS","LU0211331839.USD","LU0882574139.USD","SG9999004303.SGD","HUT","LU0354030511.USD","LU0868494617.USD","LU1934455863.HKD","IE00BMPRXN33.USD","IE00BVYPNP33.GBP","LU0553294199.USD","LU2065169927.USD","LU1145028129.USD","SKDD","SG9999015341.SGD","LU1721428933.USD","NVDB","BK4512","AIS","LU2361044865.SGD","LU0238689110.USD","07388","SGXZ51526630.SGD","GB00B4LPDJ14.GBP","LU2347655073.USD","SQCOMmain","HYNX","LU2237443549.SGD","DRIV","SG9999014567.USD","LU0557290698.USD","SGXZ23171101.USD","LU1923622291.USD","LU2047632596.USD","IXN","IE000MB6IJN5.SGD","SMU00main","GGLL","LU1430594728.SGD","SKHX","PSI","CLOD","IE00BQXX3D17.EUR","LU0345774631.USD","IE00B2B36J28.USD","LU0708994859.HKD","LU0494093205.USD","NVD","TSLR","JGRO","07766","DIPS","LU0310800965.SGD","LU2265009873.SGD","LU0029864427.USD","LU0345770308.USD","LU0353189680.USD","SGXZ81514606.USD","LU2764263203.CNY","07788","LU2097344431.USD","BOBP","LU0203347892.USD","LU0157215616.USD","LU2430703251.USD","LU2468319806.SGD","BK4560","IE00BDCRKT87.USD","LU2999663052.SGD","BK4600","LU2087625088.SGD","LU0289961442.SGD","SG9999014542.SGD","LU0210528500.USD","LU1814569148.SGD","IE00BVYPNQ40.USD","HK0000320223.HKD","LU0225283273.USD","NULC","IE00BK4W5L77.USD","LU2125909593.SGD","SG9999002232.USD","SG9999014575.USD","SG9999014898.SGD","BK4548","LU2433249047.HKD","LU1894683348.USD","LU0823414551.USD","BK4099","PALU","LU2357627491.SGD","IE00BJJMRY28.SGD","LU2250418816.HKD","LU2272731600.USD","LU1979441026.SGD","LU0162691827.USD","SG9999002224.SGD","GB00B4QBRK32.GBP","LU1242518931.SGD","LU0820561909.HKD","LU2357305700.SGD","LU1868836591.USD","LU0310799852.SGD","LU1720051108.HKD","SPAM","LU2430703095.HKD","IE00BFMHRM44.USD","LU2347655156.SGD","SKHY","CIBR","USXF","LU2168564495.EUR","LU2491049909.HKD","LU2491050154.USD","THMR","SKYY","LU0823414478.USD","LU0149725797.USD","MEDX","LU1291159041.SGD","LU2362541273.HKD","LU0072462426.USD","IE00BJJMRX11.SGD","LU2592432038.USD","LU2237443622.USD","LU0979878070.USD","SG9999015945.SGD","NVDW","LU2125154935.USD","BK4566","IE0000B7K699.USD","IE00B42XCP33.USD","LU0122379950.USD","LU0348723411.USD","MUYY","SMH","LU0957808578.USD","EFIV","LU0321505868.SGD","LU0426417589.USD","LU0861579265.USD","LU0823397103.USD","GOOX","04335","LU0061474960.USD","IE0005OL40V9.USD","LU0395794307.EUR","LU1803068623.USD","LU1852331112.SGD","TSYY","ESUM","LU2506951792.HKD","VOX","LU1803068979.SGD","LU2756315318.SGD","LU0323591593.USD","LU2286300806.USD","IE00B775SV38.USD","LU0426412945.USD","IETC","IE00BFXG1179.USD","LU1496350171.SGD","LU1551013425.SGD","LU1992135399.USD","AIQ","INTW","LU0174119429.USD","LU1642822529.SGD","LU2394011477.USD","IE000M9KFDE8.USD","LU2471134952.CNY","SCHA","IE00BMPRXQ63.HKD","LU2108987350.USD","IE00B3M56506.USD","LU0081259029.USD","LU2097344357.USD","LU2413666426.HKD","LU2237443382.USD","LU1548497426.USD","LU1868836757.USD","INTC","CHPX","LU0476273544.USD","SNVD.UK","IE00BJLML261.HKD","TMSL","BK4516","LU2237957902.USD","LU0072461881.USD","XLK","SG9999015952.SGD","METV","LU0889565833.HKD","LU1435385759.SGD","SOXY","LU1244550577.SGD","LU1280957306.USD","HK0000304805.HKD","BK4550","BK4595","LU0127658192.USD","LU0444971666.USD","LU1815336760.USD","LU1821325948.USD","BK4554","IE0009356076.USD","LU1880398554.USD","LU2065171402.SGD","IE00BQXX3C00.GBP","GOOY","CQTM","IE0001KFT4U8.USD","LU2357125470.USD","LU0980610538.SGD","LU1046421795.USD","SG9999001424.SGD","LU1791710400.SGD","SG9999015978.USD","LU0310800379.SGD","GOOW","MULL","BK4549","09388","QQQG","SG9999015986.USD","CRSH","LU1232071149.USD","LU0061475181.USD","NVDO","LU0187121727.USD","LU1244550221.USD","ARTY","LFGY","LU1894683264.USD","LU1935043536.SGD","LU0466842654.USD","HAKY","LU2362540622.SGD","WDCX","BK4082","IE0009G5SDU7.USD","LU0477156953.USD","LU1951198990.SGD","LU0006061336.USD","HUTG","LU0234572021.USD","IE00B19Z8W00.USD","LU2403377893.USD","LU1674673428.USD","SK","LU2063271972.USD","LU2237443978.SGD","LU1992135472.HKD","FTXL","LU2125154778.USD","PSWD","LU0345769128.USD","ESLG","LU1551013342.USD","BUG","INYY","TYLG","LU1815333072.USD","LU1267930490.SGD","WCLD","TRFK","IE000KEQY171.SGD","QCMU","LU1861559042.SGD","TSLO","SG9999014906.USD","LU1032955483.USD","LU2097829019.USD","QCML","DRMY","LU0203345920.USD","BK4538","LU2237443895.HKD","SNXX","SGXZ80539844.SGD","IE0002141913.USD","NVDG","LU0784385840.USD","IE0004086264.USD","LU0786609619.USD","LU0109391861.USD","LU1267930730.SGD","LU0965509010.AUD","LU0672654240.SGD","LU1084165304.USD","HK0000304797.USD","WATS","IE00B19Z3581.USD","BK4514","TSLG","BK4567","LU2456880835.USD","LU2054465674.USD","SHOC","LU2896262040.SGD","LU1861127337.USD","EGGY","LU0130517989.USD","IE0004445015.USD","LU0316494557.USD","ABFL","LU1670628061.USD","LU1633808545.USD","LU0240877869.USD","SGXZ99366536.SGD","BK4553","IE00B3PB1722.GBP","MUG","LU0323239441.USD","LU0069063385.USD","IE00B775H168.HKD","IE00BFTCPJ56.SGD","LU2168564149.EUR","LU0347712357.USD","LU2404859741.USD","HBMX","LU1868837136.USD","LU0211327993.USD","LU2430703178.SGD","LU2720916845.USD","SG9999017495.SGD","LU2272731782.SGD","LU2860962120.EUR","LU0082616367.USD","LU2242649171.HKD","LU0070217475.USD","BK4503","INT","IE00B7SZLL34.SGD","AGOX","LU2106854487.HKD","LU2271345857.HKD","LU2362541513.USD","LU0642271901.SGD","WISE","09766","LU2237443465.HKD","GGLS","BK4588","FAI","GTEK","LU0256863811.USD","LU1917777945.USD","LU1989764748.USD","GOOL","QCMD","WUGI","BK4592","LU1043141123.HKD","LU0648000940.SGD","LU0211328371.USD","LU0823421333.USD","LU1061106388.HKD","CNAV","NVII","IE00BZ1G4Q59.USD","SMOG","LU2413666699.HKD","LU0640476718.USD","LU2355687059.USD","DTCR","LU2191332357.HKD","IE000F7OJYX1.SGD","LU0784384876.USD","LU0889566641.SGD","BK4578","QQQA","TTXU","LU0130518102.USD","LU2275660780.HKD","SG9999018857.SGD","MDT","LU0107464264.USD","BK4576","IE00BLSP4239.USD","BK4573","LU0070302665.USD","LU2552382215.SGD","SG9999018865.SGD","XLC","LU0719512351.SGD","LU0143551892.USD","NVD3.UK","LU0211326839.USD","LU0859254822.USD","IE000W1ABFV2.USD","LU0823413660.USD","LU0052756011.USD","LU2236285917.USD","LU1429558221.USD","LU2092627202.USD","LU1983299246.USD","LU2148611432.USD","LU0345770993.USD","LU0742534661.SGD","IE00BK4W5M84.HKD","LU1069344957.HKD","LU1623119135.USD","LU1267930573.SGD","LU2764262908.HKD","LU2065170008.USD","LU2458330243.SGD","LU1301847155.USD","SG9999014914.USD","HK0000819398.USD","IE00B5TLWC47.USD","07366","SNVDAmain","WDCC","IE00BKDWB100.SGD","IE0009355771.USD","LU0942090050.USD","LU0251131958.USD","07709","LU0661504455.SGD","IE00B1BXHZ80.USD","HK0000532082.HKD","TSLP","TSLS","GXPC","LU1153585028.USD","LU2213496289.HKD","LU0203202063.USD","VT","IE00BFSS8Q28.SGD","CMAG","LU2552382132.HKD","BK4527","LU0240878834.USD","LU0820562030.AUD","EMSF","LU2473716301.USD","LU2543165471.USD","SNDK","LU0302445910.USD","LU0345768740.USD","LU1043141396.HKD","LU0472753341.HKD","LU2602419157.SGD","BK4608","LU1804176565.USD","LU0314106906.USD","LU1221951046.USD","LU0321505439.SGD","FCOM","BK4511","SGXZ31699556.SGD","LU2279689827.SGD","IE000BZT7R73.USD","LU1400636491.USD","FDTX","LU2087621335.USD","SNPE","TDV","LU0320765489.SGD","LU1720051017.SGD","LU0289739343.SGD","MRVX","MIC","BK4515","LU1691799644.USD","LU1732799900.SGD","IGV","LU1244550494.USD","LU2361045086.USD","LU0943347566.SGD","LU0823397285.USD","BK4023","BK4535","LU1066053197.SGD","IE000SO60NU8.SGD","LU2452424414.USD","IE00B4YYXB79.USD","QCOM","LU0096364046.USD","IE0003U64NQ7.SGD","LU2750360641.GBP","LU1983260115.SGD","LU1400636574.HKD","LU1261432733.SGD","LU1861215975.USD","LU2290526834.HKD","LU1989772840.SGD","3NVD.UK","LU0158827948.USD","SG9999014880.SGD","LU1861558580.USD","LU2462591277.SGD","LU2210149790.SGD","IE00B1XK9C88.USD","LU0265550946.USD","TSLW","BK4598","LU0820561818.USD","LU2322448791.USD","AIPI","LU2089985449.USD","LU0251142724.SGD","LU0345774391.USD","LU2048586759.USD","IE00BWXC8680.SGD","LU0949170426.SGD","COWG","LU1496350502.SGD","SNDU","SKUU","LU2360032135.SGD","HK0000306701.USD","LU1585245621.USD","LU1935042215.USD","PTF","SINTCmain","LU0289960550.SGD","LU1069347547.HKD","LU1861220033.SGD","LU1934455277.USD","LU0708995401.HKD","DELL","LU0788109477.HKD","TSL","LU1316542783.SGD","LU0496365809.HKD","BK4170","LU0545039389.USD","LU1974910355.USD","GOOGL","IE00BJTD4N35.SGD","LU0511384066.AUD","LU1718418525.SGD","OGIG","LU0823413587.USD","IE00BBT3K403.USD","LU1935043023.USD","LU2133065610.SGD","LU2326559502.SGD","IE000YTNTUN2.SGD","LU0683600562.USD","LU2264538146.SGD","LU0345768153.USD","LU0353189763.USD","LU1732800096.USD","LU1303367103.USD","TRUC","BK4534","LU1201861165.SGD","SG9999000418.SGD","SKHL","IE00BJT1NW94.SGD","IE0034235303.USD","LU0823421416.USD","LU2089984988.USD","LU2750360997.AUD","LU0949170772.SGD","LU2487616109.SGD","TLA","LU1951200564.SGD","NVYY","LU2023250330.USD","RULE","LU0648001328.SGD","NVDQ","IE000WAW04H5.SGD","LU0314104364.USD","LU2417539215.USD","GOGL","LU1506573853.SGD","DISK","IE00B5949003.HKD","LU0077335932.USD","LU1035775433.USD","MU","MRVL","LU1037948541.HKD","LU0048584097.USD","LU0417517546.SGD","LU2168564222.USD","MUZ","LU0444973449.USD","LU1066051811.HKD","PALD","LU1023059063.AUD","SMHX","LU0390134368.USD","ANV","BK4533","LU0690374615.EUR","LU0823434740.USD","LU1989764664.SGD","IE00B3T34201.USD","LU3102509885.SGD","LU0106261372.USD","LU0154236417.USD","LU0251132253.USD","TEK","LU2404859667.USD","IE00BGHQDM52.EUR","LU2491050071.SGD","LU1674673691.USD","IE00BMPRXR70.SGD","MUD","BLCK","LU0048573561.USD","LU0689472784.USD","LU2360106780.USD","LU2471134523.USD","BK4614","LU0690374961.EUR","LU2102340556.USD","BK4007","IE00BN29S564.USD","IE00B4R5TH58.HKD","IE0034235188.USD","LU2237438978.USD","MNRS","IE00BJJMRZ35.SGD","LU0203201768.USD","NVDL","FTEC","LU0345769631.USD","WANT","LU0868494708.USD","WCBR","09366","IE0034235295.USD","LU0964807845.USD","IE00B4JS1V06.HKD","IE00BZ199S13.USD","LU2211815571.USD","MVLL","TSLY","LU2168563687.JPY","LU0124676726.USD","LU2764263039.SGD","IHAK","TSII","LU2462591350.SGD","LU2168564065.EUR","AIFD","IE00BHPRN162.USD","LU2458330169.SGD","LU0208291251.USD","IE0004091025.USD","2NVD.UK","LU0354030438.USD","LU0053666078.USD","LU0965509101.SGD","LU2463028550.USD","LU0096362180.USD","LU1645745479.HKD","LU1670627923.USD","LU0054578231.USD","LU0170899867.USD","LU1923622614.USD","CHPS","LU1144417596.USD","VGT","NVDY","LU1196500208.SGD","LU2272731865.HKD","MUU","CGGO","GOOP","LU0957791311.USD","SKHA","IE00BJTD4V19.USD","LU2092937148.SGD","TESC","LU2089284900.SGD","PPH","LU1839511570.USD","IE00BKPKM429.USD","IE00BD6J9T35.USD","IE00BKVL7J92.USD","LU2089283258.USD","LU2361044949.HKD","LU1235294995.USD","IE00B19Z3B42.SGD","BK4551","CHAT","LU1116320901.HKD","LU2931357623.SGD","LU2077746001.SGD","TSLL","LU2471134879.HKD","LU0985320562.USD","CNEQ","LU1035773651.USD","LU1935042991.SGD","LU0795875086.SGD","BK4078","LU0158827781.USD","LU0689626769.HKD","LU1116320737.USD","LU1121112475.USD","LU0784385170.HKD","IE00BFSS7M15.SGD","FSMD","LU0097036916.USD","IE00B19Z9505.USD","BK4097","HK0000914660.USD","FXL","LU2028103732.USD","LINT","LU1935042488.USD","LU1267930227.SGD","LU2242650005.HKD","LU2954938101.SGD","USD","LU0787776722.HKD","LU2381873111.SGD","LU2746668974.SGD","TSLT","LU0006306889.USD","IE000ITXATA3.USD","LU1221951129.SGD","IE00BDRTCR15.USD","SKHU","LU0965508806.USD","BK4581","LU0738911758.USD","LU2111349929.HKD","NVDS.UK","NVD2.UK","LEGR","LU0726765562.USD","LU2294711713.HKD","LU1923623000.USD","LU2420271590.USD","NVC","SG9999014559.SGD","SKHYV","LU1201861249.SGD","LU0528227936.USD","BK4543","LU1699723380.USD","LU1989772923.USD","LU0267386448.USD","IE00B7KXQ091.USD","LU1003077747.HKD","LU1169589451.USD","LU0210536198.USD","LU1400636657.SGD","LU1066051225.USD","LU1880398471.USD","SOXQ","LU0061474705.USD","LU0109392836.USD","SKHZ","LU0056508442.USD","LU1059921491.USD","LU1366192091.USD","LU2023250843.SGD","LU0130103400.USD","LU1267930813.SGD","LU1712237335.SGD","LU0823434583.USD","LU0823411888.USD","LU2237957811.SGD","LU2023250504.SGD","LU0784383803.USD","BK4077","LU0432979614.USD","LU0320765059.SGD","IE00BVYPNV92.GBP","HK0000914686.HKD","SCHM","ELOL","LU2552382058.USD","LU2471134796.USD","LU0795875169.SGD","NVIW.SI","BK4585","BK4561","BK4579","IE0004445239.USD","LU1989771016.USD","PANW","SGXZ44715902.SGD","TSLZ","09788","LU2210150020.SGD","LU0912757837.SGD","LU2360107168.USD","HK0000306685.HKD","SOXX","LIT","LU2112291526.USD","IE00BVYPNW00.USD","IE00B3SWFQ91.USD","LU1127390331.HKD","LU2125909759.SGD","IE00BQXX3F31.USD","LU1169590202.USD","LU1868837300.USD","LU1057294990.SGD","LU0080751232.USD","LU1119994496.HKD","SKHN","BK4587","IE00B3S45H60.SGD","SPTE","BK4574","LU2505996509.AUD","PANG","NVDU","LU2095319765.USD","LTL","LU0011850046.USD","BAI","LU1037948897.HKD","LU0963586101.USD","LU0128525689.USD","BK4604","LU0211326755.USD","LU2244417387.USD","IE000Q6AESB8.SGD","LU1778281490.HKD","SNDC","LU0265550359.USD","LU0175139822.USD","LU0128525929.USD","LU1366333091.USD","XNTK","IE00BN8TJ469.HKD","LU2322448957.HKD","LU2637965513.SGD","OPTZ","IDRV","TESL","LU0057025933.USD","LU2083900584.USD","NVDD","HK0000320264.USD","TSLI","LU1791710582.SGD","LU2125909916.SGD","LU0276348264.USD","LU0994945656.USD","LU2100268510.USD","BK4529","LU1064131342.USD","LU0210533765.USD","LU0724617625.USD","NVDX","TTEQ","LU0133085943.USD","LU1956131251.USD","TSLA","LU2125909247.SGD","LU0198837287.USD","LU0138981039.USD","TEST","LU1914381329.SGD","LU1242518857.USD","IE00BGHQF631.EUR","LU0792757196.USD","LU1823568750.SGD","IE00BLSP4452.SGD","LU1571399168.USD","LU0965509283.SGD","LU1988902786.USD","LU2746668461.USD","LU0079474960.USD","LU1629891620.HKD","LU0094547139.USD","WLDR","LU0215105999.USD","LU0308772762.SGD","LU1868836914.USD","LU2249611893.SGD","LU2756315664.SGD","SG9999015358.SGD","BK4141","ROM","LU0976567544.SGD","NVDS","BK4575","ILDR","LU1202635105.USD","TSDD","LU0342679015.USD","CLSE","SNDG","LU2462157665.USD","LU0234570918.USD","DLLL","IE00BSNM7G36.USD","LU0477156797.USD","GB00BDT5M118.USD","LU1066051498.USD","XDAT","LU0130102774.USD","STSLAmain","BK4602","TSLQ","BK4555","GPRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664568448","title":"Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2664568448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664568448?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:49","pubTimestamp":1788263354,"startTime":"0","endTime":"0","summary":"FACTBOX-Global pharma companies that have publicly announced Trump drug pricing agreementsSept 1 (Reuters)-U.S. President Donald Trump has struck drug-pricing deals with more than 20 pharmaceutical co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4N44T0TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","IE000MB6IJN5.SGD","LU2324357040.USD","LU2106854487.HKD","LU1201861249.SGD","LU2237438978.USD","LU0097036916.USD","SG9999001176.USD","LU0225284248.USD","LU0289739343.SGD","LU1979441026.SGD","SG9999002224.SGD","LU2456880835.USD","LU2023251221.USD","688235","IE00B19Z3B42.SGD","LU0889565916.HKD","LU0225771236.USD","LU0162691827.USD","LU2756315664.SGD","LU0823434583.USD","GSKH","SGXZ99366536.SGD","LU0820561909.HKD","LU2111349929.HKD","LU0006306889.USD","IE0002141913.USD","SG9999015945.SGD","LU2491050154.USD","VHT","AZNH","LU0861579265.USD","LU1196500208.SGD","IE00BVYPNW00.USD","LU1043141396.HKD","JDOC","04332","LU0289961442.SGD","LU0942090050.USD","LU1037948541.HKD","LU0174119429.USD","FTXH","LU0985320562.USD","NVO","SG9999015341.SGD","IE0001KFT4U8.USD","TMED","LU0545039389.USD","LU2361044949.HKD","IXJ","LU1280957306.USD","LU1914381329.SGD","IE00BFSS8Q28.SGD","LU1059921491.USD","LU1145028129.USD","LU1244550577.SGD","LU0310800379.SGD","LU0061475181.USD","LU0417517546.SGD","TBXU","FHLC","LU0661504455.SGD","LU1720051108.HKD","SG9999018857.SGD","BK0239","LU1923622614.USD","LU1778281490.HKD","LU1127390331.HKD","PJP","LU1868836591.USD","LU1718418525.SGD","LU0792757196.USD","IE00BJJMRX11.SGD","IYH","LU1934455194.USD","XLV","CURE","BK4505","LU0203201768.USD","BMY","IE00BJLML261.HKD","LU0210536198.USD","LU2592432038.USD","LU0823416689.USD","IE000BZT7R73.USD","LU2242652126.USD","SG9999015358.SGD","IE0000B7K699.USD","LU0456855351.SGD","LU1974910355.USD","LU0648001328.SGD","LU0203347892.USD","MEDX","IE00BK4W5L77.USD","LU0158827948.USD","LU0053666078.USD","LU2213496289.HKD","LU2491050071.SGD","BK4007","LU1267930813.SGD","LU0511384066.AUD","PAWZ","IE00BDGV0183.EUR","SGXZ57979304.SGD","LU1983299246.USD","SG9999014898.SGD","GB00BDT5M118.USD","LU0353189763.USD","LU1548497426.USD","ELIS","LU1267930490.SGD","LU1585245621.USD","LU1496350502.SGD","PFE","NVOH","IE00B19Z3581.USD","AZN","LU0203202063.USD","LU1035775433.USD","IE00B1BXHZ80.USD","LU2487616109.SGD","LU1232071149.USD","IE00B3PB1722.GBP","LU1804176565.USD","LU0321505439.SGD","BK4585","LU1074936037.SGD","LU2430703178.SGD","LU0114720955.EUR","BK4581","LU0096364046.USD","LU2237443465.HKD","LU2168564222.USD","IE00BKDWB100.SGD","BBIO","BK4534","LU2237443382.USD","BK4583","LU2063271972.USD","IE00BFTCPJ56.SGD","GILD","BK4550","LU0128525929.USD","LU0124676726.USD","LU2750360641.GBP","LU0708994859.HKD","LU1868837300.USD","LU2746668974.SGD","LU2462157665.USD","IBBQ","SG9999017495.SGD","LU1221951129.SGD","LU0225283273.USD","LU0320765489.SGD","LU0949170772.SGD","LU2023250504.SGD","LU2461242641.AUD","LU2430703095.HKD","LU0109394709.USD","LU0154236417.USD","LU1366192091.USD","IE00BFSS7M15.SGD","LU2357627491.SGD","AGNG","LU1929549753.HKD","LU0234570918.USD","LU0795875169.SGD","LU2362541513.USD","LU2129689605.HKD","IE0004445239.USD","SG9999014542.SGD","LU2236285917.USD","LU0553294199.USD","LU1989772840.SGD","LU0683600562.USD","LU2089284900.SGD","IE00BZ1G4Q59.USD","LU0354030438.USD","LU0477156953.USD","LU2087625088.SGD","IE00BVYPNV92.GBP","LU1732799900.SGD","LU0882574055.USD","JNJ","LU0320765059.SGD","GLAM","LU0795875086.SGD","LU0122379950.USD","SG9999018865.SGD","LU1267930730.SGD","IE00B4R5TH58.HKD","LU2462591350.SGD","SG9999014880.SGD","LLY","IE00BWXC8680.SGD","LU2417539215.USD","LU0787776722.HKD","LU0980610538.SGD","LU1883839398.USD","SGXZ81514606.USD","LU0345769631.USD","IE0005OL40V9.USD","LU0130102774.USD","LU0265550359.USD","LU2237443978.SGD","LU0109391861.USD","LU0432979614.USD","ONC","LU1720051017.SGD","LU0058720904.USD","LU0158827781.USD","SG9999001440.SGD","LU2347655156.SGD","LU0738911758.USD","SG9999014559.SGD","LU1066051498.USD","LU2237443622.USD","LU0170899867.USD","LU1267930573.SGD","LU1934455863.HKD","GDOC","LU1236620750.USD","LU0943347566.SGD","LU1093756168.USD","LU1496350171.SGD","LU0130517989.USD","LU1868836914.USD","LU0069063385.USD","LU1323610961.USD","LLYZ","LLII","LU1712237335.SGD","LU1670628061.USD","LU0708995401.HKD","MEDI","LU0640476718.USD","LU2471134952.CNY","LU1244550494.USD","IE00BK4W5M84.HKD","IE00BFXG1179.USD","LU2403377893.USD","IE00BSNM7G36.USD","OZEM","IE00B4JS1V06.HKD","BK4559","LU0689626769.HKD","LU0965509283.SGD","LU1061106388.HKD","BK7067","LU1571399168.USD","LU1093756325.SGD","LU0726765562.USD","LU2750360997.AUD","SG9999001176.SGD","LU0238689110.USD","LLYX","LU1236620834.HKD","LU2125909247.SGD","ELIL","LU2361045086.USD","LU0072461881.USD","IE0009355771.USD","LU0395794307.EUR","LU1032955483.USD","SGXZ51526630.SGD","LU2089283258.USD","IE00B7KXQ091.USD","LU0323591593.USD","LU2471134523.USD","LU2347655073.USD","LU0471298694.HKD","LU1894683264.USD","LU1917777945.USD","LU1670711040.USD","LU0237698245.USD","LU2125154778.USD","LU0345770308.USD","LU1069344957.HKD","NVOX","SGXZ31699556.SGD","LU1261432733.SGD","LU1691799644.USD","BK4504","LU0426412945.USD","LU0823434740.USD","IE0034235303.USD","LU0256863811.USD","LU2471134879.HKD","LU2357305700.SGD","LU0868494708.USD","BIB","LU0965508806.USD","LU1551013425.SGD","LU0320765646.SGD","IE0002270589.USD","RXL","LU1116320737.USD","IE00BLSP4452.SGD","LU2168564149.EUR","NVOC","SG9999015978.USD","LU2430703251.USD","LU1066051811.HKD","IHE","LU0098860793.USD","IE00BGHQF631.EUR","TRUH","LU0256863902.USD","IE00BJJMRZ35.SGD","LU0985481810.HKD","LU1121112475.USD","LU0472753341.HKD","IE00BJJMRY28.SGD","LU1670711123.USD","GSK","LU1829250122.USD","LU1228905037.USD","LU1066053197.SGD","LU2242646821.SGD","LU1023059063.AUD","LU2089984988.USD","BK4516","LU0786609619.USD","LU0310799852.SGD","IE00BKPKM429.USD","THNR","IE000F7OJYX1.SGD","LU0267386448.USD","LU2237443895.HKD","LU0203345920.USD","LU2468319806.SGD","LU0070217475.USD","LU2746668461.USD","LU0265550946.USD","BBH","LU1162221912.USD","LU2552382058.USD","LU0316494557.USD","LU2108987350.USD","LU0133085943.USD","LU2028103732.USD","LU2237443549.SGD","SG9999014567.USD","ABBV","LU1988902786.USD","LU0057025933.USD","LU1623119135.USD","LU0320765992.SGD","LU0306807586.USD","LU1674673691.USD","IE00B775H168.HKD","LU2433249047.HKD","LU0210528500.USD","IE000SO60NU8.SGD","WDNA","LU0672654240.SGD","LU0353189680.USD","LU2491049909.HKD","LU0994945656.USD","IE00B42XCP33.USD","LU1629891620.HKD","LU1868837136.USD","LU0689472784.USD","LU1839511570.USD","SG9999013999.USD","NVS","LU0345770993.USD","LU1814569148.SGD","LU0882574139.USD","LU1941712264.USD","MHIP","IE00BN8TJ469.HKD","LU0211328371.USD","IE00BBT3K403.USD","LU0198837287.USD","LU0385154629.USD","LU2271345857.HKD","LU1066051225.USD","GSK.UK","IE0004445015.USD","LU1037948897.HKD","IBB","IE00BLSP4239.USD","LU0466842654.USD","LU2596442595.SGD","PBE","IE00BKVL7J92.USD","IE00B1XK9C88.USD","LU2602419157.SGD","IE00BJT1NW94.SGD","LU1670710661.SGD","LU1674673428.USD","LU0912757837.SGD","SG9999002232.USD","LU0211327993.USD","LU2133065610.SGD","LU2112291526.USD","LU0208291251.USD","LU0070302665.USD","LU2896262040.SGD","LU1069347547.HKD","LU0079474960.USD","LU0820562030.AUD","LU0545562505.USD","CANC","LU1430594728.SGD","LU2125909593.SGD","PPH","LU2505996509.AUD","AMGN","LU2125154935.USD","LU0266013472.USD","MRK","SG9999015952.SGD","LU0889566641.SGD","LU0029864427.USD","LU2471134796.USD","SG9999014906.USD","HRTS","LU2362540622.SGD","LU1732800096.USD","LU0306806265.USD","BMED","LU0354030511.USD","LU1934455277.USD","LU1032466523.USD","LU0965509101.SGD","LU1670710588.SGD","LU2211815571.USD","LU1894683348.USD","LU0106261372.USD","LU1935042991.SGD","BK7501","LU0964807845.USD","LU0426417589.USD","BK4578","LU1670627923.USD","LU1868836757.USD","LU1551013342.USD","SG9999014575.USD","IE00B2B36J28.USD","06160","ILDR","LU1064131342.USD","LU2756315318.SGD","LU1116320901.HKD","LU2360032135.SGD","SG9999011175.SGD","SGXZ80539844.SGD","LU0471298777.SGD","LU2168564495.EUR","BK4533","BK7511","LU0859254822.USD","LU2361044865.SGD","LU2265009873.SGD","LU0211331839.USD","LU1228905540.USD","BK4568","LU2023250330.USD","LU2552382215.SGD","LU2264538146.SGD","LU2552382132.HKD","LU1941712348.USD","CSL.AU","LU1003077747.HKD","LU1244550221.USD","LU2129689431.USD","IE00B3T34201.USD","LU1057294990.SGD","SG9999014914.USD","LU1043141123.HKD","SG9999015986.USD","LU1035773651.USD","IE000WAW04H5.SGD","LU1699723380.USD","BK4592","LU0868494617.USD","BK4139","LU0234572021.USD","LU1506573853.SGD","REGN","SG9999003800.SGD","LU2362541273.HKD","LU0345769128.USD","BK4588","IE00BN29S564.USD","LU1989772923.USD","LU2505996681.GBP","LU1291159041.SGD","IE00B7SZLL34.SGD","LU2087621335.USD","LU1989771016.USD","IE000M9KFDE8.USD","LU0321505868.SGD","LU1221951046.USD","LU2023250843.SGD","LU2168563687.JPY","BK4532","BK7508","LU2168564065.EUR","BK4566","BK4599","LU0820561818.USD","LU2129689514.USD","LU0094547139.USD","LU2360106947.USD","LU0965509010.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855406","title":"Why Novartis Stock is Heading for Its Best Day Since 2023 After 3 Patient Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855406","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855406?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:34","pubTimestamp":1788262440,"startTime":"0","endTime":"0","summary":"Novartis released a mixed bag of clinical updates, pausing trials for one drug after a spate of patient deaths while simultaneously revealing positive data for a pill that analysts view as a potential","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0208291251.USD","BK4578","BK4585","BK4007","IE0009355771.USD","LU0211331839.USD","IE00BJJMRZ35.SGD","BK4588","PPH","BK4532","LU0320765489.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","MEDX","LU0070302665.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664580608","title":"Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2664580608","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664580608?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:34","pubTimestamp":1788258840,"startTime":"0","endTime":"0","summary":"Novartis shares rose after the drugmaker reported positive results from two late-stage trials in the most common form of multiple sclerosis, saying its new pill helped patients experience fewer flare-","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","MEDX","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","LU0208291251.USD","IE00B2B36J28.USD","BK4578","IE0009355771.USD","BK4532","IE00B4R5TH58.HKD","PPH","LU0320765489.SGD","BK4588","LU0070302665.USD","LU0211331839.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664580128","title":"Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2664580128","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664580128?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258656,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced positive topline results from its Phase III Remodel-1/-2 trials of remibrutinib in relapsing multiple sclerosis. Remibruti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-results-from-phase-iii-remodel-1-2-trials-of-remibrutinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-results-from-phase-iii-remodel-1-2-trials-of-remibrutinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4588","MEDX","IE00B4R5TH58.HKD","BK4585","IE0009355771.USD","IE00B2B36J28.USD","LU0211331839.USD","LU0070302665.USD","PPH","NVS","BK4578","LU0208291251.USD","BK4532","IE00BJJMRZ35.SGD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664985383","title":"Novartis halts autoimmune CAR-T trials following three deaths, Reuters says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664985383","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664985383?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258648,"startTime":"0","endTime":"0","summary":"Novartis (NVS) has paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after thr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","IE0002141913.USD","IBB","IE00BJT1NW94.SGD","HYLG","TBXU","LU0208291251.USD","IE00BFTCPJ56.SGD","GNOM","IDNA","FBT","IE0009355771.USD","BK4578","BMED","SYNB","BK4007","BK4585","IE00B2B36J28.USD","LU0070302665.USD","LU0211331839.USD","BK4588","IE00B4R5TH58.HKD","NVIB","IE00BJJMRZ35.SGD","LU0320765489.SGD","NVS","GDOC","PPH","BK4532","CNCR","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664383293","title":"Novartis Says Remibrutinib Significantly Reduces Relapse Rates in Phase 3 Multiple Sclerosis Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383293","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383293?lang=en_us&edition=fundamental","pubTime":"2026-09-01 16:51","pubTimestamp":1788252718,"startTime":"0","endTime":"0","summary":"Novartis  said Tuesday that phase 3 trials of remibrutinib showed significantly reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis.The trials met their primary endpoints and showed that remibrutinib was superior to teriflunomide on all key secondary measures.A preplanned combined analysis also showed a positive trend in three month confirmed disability progression and nominally significant results for six month confirmed disability progression, Novartis said.Remibrutinib also demonstrated a favorable safety profile with no liver safety signal, the company said.Novartis shares were over 4% higher in Tuesday premarket activity.Price: 158.47, Change: +6.41, Percent Change: +4.22","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0070302665.USD","IE0009355771.USD","BK4007","NVS","LU0211331839.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4532","BK4578","LU0320765489.SGD","LU0208291251.USD","BK4588","IE00BJJMRZ35.SGD","PPH","IE00B2B36J28.USD","BK4585","MEDX","IE00BFTCPJ56.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132713513","title":"Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise","url":"https://stock-news.laohu8.com/highlight/detail?id=1132713513","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132713513?lang=en_us&edition=fundamental","pubTime":"2026-09-01 15:50","pubTimestamp":1788249011,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical giant Novartis AG (NVS.US) is experiencing a stark contrast in its neuro-immunology pipeline, as progress in one area is overshadowed by a serious setback in another. The company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","BK4588","NVS","BK4007","PPH","BMED","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","01477","LU0208291251.USD","IE00B2B36J28.USD","MEDX","PSYK","IBBQ","BK1574","IE00B4R5TH58.HKD","IE0009355771.USD","IE0002141913.USD","IBBJ","BK4585","BK1191","MDTX","BK4532","BK4578","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664809308","title":"Novartis Pauses Autoimmune Cell Therapy Studies After Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=2664809308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664809308?lang=en_us&edition=fundamental","pubTime":"2026-09-01 11:50","pubTimestamp":1788234600,"startTime":"0","endTime":"0","summary":"Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.The Swiss pharmaceutical company temporarily ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","LU1718418525.SGD","LU1883839398.USD","LU1236620834.HKD","MEDX","BK4578","IE00B4R5TH58.HKD","NVS","LU1670710661.SGD","IHE","LU1670711123.USD","LU1032466523.USD","LU0306806265.USD","LU1261432733.SGD","LU2360032135.SGD","LU1093756168.USD","LU0070302665.USD","LU0306807586.USD","IE00BJJMRZ35.SGD","LU0985481810.HKD","IE00BSNM7G36.USD","LU0096364046.USD","BK4007","LU1323610961.USD","LU0432979614.USD","FTXH","LU1983299246.USD","IE0009355771.USD","LU1571399168.USD","BK4534","IE00BFXG1179.USD","PPH","LU2133065610.SGD","BK4532","LU0321505868.SGD","LU1670710588.SGD","LU1868837136.USD","LU1989771016.USD","LU0061475181.USD","IE00BJT1NW94.SGD","LU2596442595.SGD","LU1585245621.USD","LU0882574055.USD","BK4559","LU1670711040.USD","IE0002141913.USD","BK4581","LU0208291251.USD","BMY","LU2242646821.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664002175","title":"Novartis AG Falls Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2664002175","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664002175?lang=en_us&edition=fundamental","pubTime":"2026-09-01 00:15","pubTimestamp":1788192900,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  slipped 0.4% to CHF123.26 Monday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 0.8% to 14,286.43.Novartis AG closed CHF8.24 below its 52-week high of CHF131.50, which the company reached on July 29, 2026.Trading volume was 2,544,960, compared to the 50-day average trading volume of 2,260,389.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765489.SGD","BK4588","LU0208291251.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","MEDX","LU0070302665.USD","LU0211331839.USD","PPH","IE0009355771.USD","BK4578","BK4007","IE00BJJMRZ35.SGD","BK4585","IE0002141913.USD","BK4532","IE00B2B36J28.USD","NVS","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663043488","title":"Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2663043488","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663043488?lang=en_us&edition=fundamental","pubTime":"2026-08-30 07:30","pubTimestamp":1788046226,"startTime":"0","endTime":"0","summary":"Gilead Sciences stock has delivered very strong gains over the past few years, yet current valuation checks still suggest the shares screen as inexpensive on several metrics. The question for investors is how that strong track record and the latest product approvals align with a profile that continues to lean cheap.\n\nOver 5 years the stock has returned about 143%, which puts recent moves in the context of a long, powerful run that investors now need to judge against today’s pricing.\nThe...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-stays-cheap-after-a-143-five-year-run","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/gilead-gild-stock-stays-cheap-after-a-143-five-year-run","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2468319806.SGD","TBXU","SG9999015945.SGD","BK4588","BK4578","LU0234570918.USD","LU1066053197.SGD","BK4532","LU1061106388.HKD","LU1585245621.USD","LU0965508806.USD","LU0882574055.USD","BK4568","LU0965509010.AUD","LU2112291526.USD","LU0823416689.USD","BIB","IE00BKVL7J92.USD","BK4566","LU1934455863.HKD","LU1934455277.USD","LU2324357040.USD","TMED","GILD","IE00B19Z3B42.SGD","LU1066051498.USD","LU0114720955.EUR","BK4550","LU1430594728.SGD","IE00B3T34201.USD","IBB","LU1571399168.USD","LU1934455194.USD","SG9999015978.USD","BMED","IBBQ","BBH","LU0122379950.USD","LU0965509283.SGD","MEDI","BK4583","BK4139","LU0058720904.USD","LU1023059063.AUD","LU1839511570.USD","LU0289739699.SGD","LU2089984988.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663701587","title":"Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2663701587","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663701587?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:35","pubTimestamp":1787949300,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slid 2.14% to $145.68 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.25% to 7,711.76 and Dow Jones Industrial Average  falling 0.02% to 53,559.99.Gilead Sciences Inc. closed 7.38% short of its 52-week high of $157.29, which the company achieved on February 11th.The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson  rose 0.85% to $268.04, Pfizer Inc.  fell 0.21% to $27.96, and Abbott Laboratories  rose 0.79% to $112.47.Trading volume  remained 3.2 million below its 50-day average volume of 7.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled August 28, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0058720904.USD","LU2112291526.USD","LU2087621335.USD","LU1061106388.HKD","LU2468319806.SGD","LU2357627491.SGD","BK4139","BK4588","LU1057294990.SGD","BBH","IE00BKVL7J92.USD","LU1778281490.HKD","LU1674673428.USD","GILD","LU0320765992.SGD","LU0965508806.USD","BK4568","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU1839511570.USD","LU0109394709.USD","LU1934455194.USD","LU1934455277.USD","LU1934455863.HKD","IE00B19Z3581.USD","LU0965509010.AUD","BK4583","MEDI","LU0889565916.HKD","SG9999015986.USD","BMED","SG9999015978.USD","TMED","LU0965509283.SGD","LU0122379950.USD","LU0965509101.SGD","IE00BZ1G4Q59.USD","BK4578","LU0114720955.EUR","LU1066053197.SGD","SG9999015952.SGD","LU0859254822.USD","LU1674673691.USD","LU1037948541.HKD","LU1066051498.USD","LU2324357040.USD","BK4585","LU2089984988.USD","BK4550","TBXU","LU0823416689.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0882574055.USD","SG9999015945.SGD","LU1571399168.USD","BK4532","LU1023059063.AUD","LU1037948897.HKD","LU1430594728.SGD","IBB","IE0002270589.USD","LU1585245621.USD","LU0861579265.USD","BIB","IBBQ","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663018885","title":"Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663018885","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663018885?lang=en_us&edition=fundamental","pubTime":"2026-08-29 01:20","pubTimestamp":1787937637,"startTime":"0","endTime":"0","summary":"Gilead Sciences stock was down roughly 2% on Friday alongside an FDA update concerning HIV drug Bixlenvo.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/gilead-sciences-stock-gild-slips-2-despite-fda-approval-of-bixlenvo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/gilead-sciences-stock-gild-slips-2-despite-fda-approval-of-bixlenvo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1037948541.HKD","BK4566","LU1934455863.HKD","IE00B19Z3B42.SGD","LU1057294990.SGD","IE00B19Z3581.USD","IBB","GILD","LU1778281490.HKD","LU1037948897.HKD","TBXU","BK4139","SG9999015986.USD","BBH","LABU","LU1066053197.SGD","BK4578","BMED","IE00BKVL7J92.USD","TMED","LU0859254822.USD","BK4585","LU0122379950.USD","LU2357627491.SGD","LU0823416689.USD","LU1585245621.USD","LU2112291526.USD","LU0320765992.SGD","LU0965509010.AUD","SG9999015978.USD","BIB","IE0002270589.USD","SG9999015945.SGD","IE00BSNM7G36.USD","LU0889565916.HKD","BK4588","LU1571399168.USD","LU0114720955.EUR","LU0882574055.USD","IE00B3T34201.USD","LU1934455194.USD","LU1066051498.USD","LU0109394709.USD","IE00B7SZLL34.SGD","LU0965509101.SGD","LU1934455277.USD","BK4532","MEDI","IBBQ","LU1674673691.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":106,"code":"91000000","status":"200"}]}}